The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade-Reference-Cited by-同舟云学术

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Published:2018-03 Issue:11 Volume:22 Page:2978-2994
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Schaer David A.,Beckmann Richard P.,Dempsey Jack A.,Huber Lysiane,Forest Amelie,Amaladas Nelusha,Li Yanxia,Wang Ying Cindy,Rasmussen Erik R.,Chin Darin,Capen Andrew,Carpenito Carmine,Staschke Kirk A.,Chung Linda A.,Litchfield Lacey M.,Merzoug Farhana F.,Gong Xueqian,Iversen Philip W.,Buchanan Sean,de Dios Alfonso,Novosiadly Ruslan D.,Kalos Michael^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference36 articles.

1. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells;Antony;J. Immunol.,2005

2. CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression;Appleman;J. Immunol.,2000

3. mTOR regulates memory CD8 T-cell differentiation;Araki;Nature,2009

4. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma;Castle;BMC Genomics,2014

5. The senescence-associated secretory phenotype: the dark side of tumor suppression;Coppé;Annu. Rev. Pathol.,2010

Cited by 336 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

2. Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules;European Journal of Medicinal Chemistry;2024-09

3. Combination of chemotherapy and endocrine treatment in breast cancer — is it still a taboo?;Oncology in Clinical Practice;2024-08-21

4. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy;Journal of Translational Medicine;2024-08-09

5. INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death;Oncotarget;2024-07-12